Cosmo Pharmaceuticals N.V Capital Reinvestment Ratio
Cosmo Pharmaceuticals N.V capital reinvestment ratio. Cosmo Pharmaceuticals N.V (C43) has a Capital Reinvestment Ratio of 0.18x as of June 2022, meaning it reinvests 0% of its operating cash flow (€6.28 Million) in capital expenditures (€1.11 Million). Check C43 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Cosmo Pharmaceuticals N.V (2016–2024)
Capital reinvestment ratio of Cosmo Pharmaceuticals N.V from 2016 to 2024. This chart tracks Cosmo Pharmaceuticals N.V's Capital Reinvestment Ratio across 6 annual periods. Also explore C43 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Cosmo Pharmaceuticals N.V Capital Reinvestment Ratio by Year (2016–2024)
Cosmo Pharmaceuticals N.V capital reinvestment ratio by year from 2016 to 2024. For the full cash flow conversion analysis, see C43 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €162.41 Million | €5.65 Million | ▼ -92.4% |
| 2023 | 0.46x | €33.62 Million | €15.31 Million | ▲ +107.0% |
| 2022 | 0.22x | €33.23 Million | €7.31 Million | ▼ -49.4% |
| 2021 | 0.44x | €12.61 Million | €5.49 Million | ▲ +37.1% |
| 2020 | 0.32x | €12.98 Million | €4.12 Million | ▼ -62.6% |
| 2016 | 0.85x | €21.69 Million | €18.43 Million | — |